Investor disappointment as vaccines again come up short, despite the Q3 beat
30/10/24 -"Even the better-than-expected Q3 results failed to impress investors, as GSK’s key vaccines fell short of the street’s estimates, causing worries for future growth. Nonetheless, other areas ..."
Pages
62
Language
English
Published on
30/10/24
You may also be interested by these reports :
15/01/26
In late-2024, when we last teased the story of DiaSorin (BUY; Italy), a family-owned in-vitro diagnostic company specialising in immunodiagnostics ...
09/01/26
Hikma, over the years, has struggled to create shareholder wealth, perhaps because of its inability (until now) to develop biosimilars on its own. ...
31/12/25
Keeping in mind the underwhelming late-stage results of the immunology drug, amlitelimab, and a few other R&D setbacks in recent years, we have ...
30/12/25
Over the last three years, GSK’s earnings have exceeded the market’s expectations on most occasions. Moreover, the firm’s R&D efforts have yielded ...